Generex Biotechnology Initiates Social Media Campaign for Its Corporate and e-Commerce Websites

WORCESTER, Mass., Sep 1, 2010 (GlobeNewswire via COMTEX) -- Generex Biotechnology Corporation (Nasdaq: GNBT | PowerRating), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today it has initiated an integrated Social Media campaign across its corporate website (www.generex.com) as well as its e-commerce websites for its various consumer diet, glucose raising and energy products, including Glucose RapidSpray(TM) (www.GlucoseRapidSpray.com), Crave-NX(TM) Diet Spray (www.CraveNx.com), BaBoom!(TM) Energy Spray (www.BaBoomEnergySpray.com) and Glucose RapidSpray(TM) for Pets(TM) (www.GlucoseRapidSprayPets.com). Through Facebook, Twitter and various other online community destinations, these social media campaigns serve to increase brand awareness, build online community engagement and enhance long-term customer loyalty via relevant content postings and on-demand conversations.

"We are excited about utilizing the social media campaign to introduce and communicate about our products and platforms within the vast online media landscape", said Rose C. Perri, Generex's Chief Operating Officer. "We consider this type of service as having a growing role in the future of patient, customer and investor communications."

About Generex Biotechnology Corporation

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, buccal insulin (Generex Oral-lyn(TM)), which has been approved in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.